posted strong growth of 11%. This was well in excess of the 3%-7% growth posted by early-stage U.S. peers Covance and Charles River, although WuXi is growing off a much smaller base. Longer term, we expect the U.S. business to
* Offer represents premium of 32 pct to Covance 's Friday closing
* Sapient, Covance rally on heavy volume; both to be bought
Covance announced that it has agreed to be acquired by LabCorp for a mixture of cash and stock equal to approximately $105 per Covance share. For Covance shareholders, we think LabCorp’s offer represents an attractive
announcement of its impending acquisition of Covance , we think investors may not fully ..... incorporating our assumptions about the Covance business and LabCorp's financing ..... raising our fair value estimate on Covance to the $105 offer price. We think
Nov 3 (Reuters) - Laboratory Corp of America Holdings , a provider of healthcare diagnostic services, said it would buy contract research company Covance Inc for about $6.1 billion in cash and stock.
year. We believe this segment is the best comparison to Covance 's early-stage business, and Charles River’s performance compares favorably to Covance 's early-stage reported revenue of 7.7%. While Charles
rather than a more concerning slowdown in demand. Based on the strong book/bill ratios we have seen out of its peers Covance and ICON, which have already reported this quarter, we are inclined to agree with management. The firm's less attractive
Covance reported first-quarter results that slightly ..... industrywide overcapacity and weak demand, but Covance has shown signs of improvement. The segment has ..... however, it was boosted by 10.9% growth in Covance ’s large central lab business. The clinical
growth since 2008. Management stated it is stealing market share from competitors, which we believe is accurate given that Covance reported just 5% revenue growth for its early-stage business in the fourth quarter.